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different methods of mobilization or if long term transplant
outcomes are impacted.Table 1
N Censored 1 yr
survival
rate (%)
3 yr
survival
rate (%)
5 yr
survival
rate (%)
Median
(months)
95% CL
(months)
PFS 29 18 78 68 41 44.7 (17.3, NA)
OS-HSCT 29 20 81 66 66 112.0 (13.9, NA)
OS-DX 29 20 89 66 66 117.2 (18.7, NA)144
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The hematopoietic cell transplantation speciﬁc comorbidity
index (HCT-CI) has been proven to be a valuable tool in
allogeneic stem cell transplant (ASCT) recipients to predict
overall survival. There are few studies that use the HCT-CI for
evaluating autologous stem cell transplantation. Our insti-
tution performs autologous stem cell transplants in a variety
of settings, from completing the whole transplant process
inpatient to instituting their preparative regimen through
transplant and engraftment in the outpatient setting. We
retrospectively reviewed our experience of 250 autologous
stem cell transplants who had a diagnosis that included
Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's
Lymphoma, and Testicular Carcinoma that were either
treated inpatient for their hospital course or were prepared
in the outpatient setting and/or were discharged very early
in their transplant course (day-1 or within three days of their
autologous transplant). The median age of the inpatient
transplant group was 63.5 compared to the outpatient group
that was 58, P< 0.006. The average comorbidity index for the
inpatient group was 2.086 compared to the outpatient group
1.23, P < 0.001. In conclusion, our institution, using the HCT-
CI and age for autologous stem cell transplantation helps to
identify those candidates that are more successfully treated
in the inpatient setting and the outpatient setting. This study
was limited by its retrospective nature, small size and single
center experience. Prospective randomized studies are
needed to determine whether or not the HCT-CI in autolo-
gous stem cell transplantation is truly effective.145
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Background: There is no current standard of care for
patients with newly diagnosed AL amyloidosis. Autologous
HSCT is a potential option, but has been limited in its use due
to increasd treatment-relatedmortality (TRM) (38% from onerandomized study). Two large retrospective analyses showed
improved overall survival (OS) (70% at 4 yrs and 47% at 5 yrs)
of AL amyloid patients undergoing aHSCT compared to
control (40% at 4 yrs) with TRM of 13%.
Methods: We retrospectively analyzed the outcomes of 29
newly diagnosed AL amyloidosis patients who underwent
aHSCT between 10/1998 and 5/2012. Hematologic responses
were evaluated, along with post-transplant survival and
TRM. Progression-free survival (PFS) and (OS) were deter-
mined using the Kaplan-Meier method.
Results: Of the patients transplanted, 13 were female and 16
weremale.Median age at aHSCTwas 56 (range 26-71). Eleven
(38%) had involvement of at least 2 organs. Median brain
natriuretic peptide and troponin available in 20 patientswere
109 pm/ml (range 24-502) and 0.02ng/ml (range 0.01-1.17).
Twenty-onepatients (72%) receivedhighdoseMelphalan 200
mg/m2. Median CD34+ infused stem cells was 5.00 x 106/kg.
No patients received ﬁlgrastim or other colony stimulating
factor. Time to neutrophil and platelet engraftment were 12
and 17 days, respectively. Three months hematologic
response was available in 22 patients and showed complete
response, partial response, and stable disease in 15(68%), 2
(10%) and 5(22%), respectively. The 1, 3, and 5 year PFS were
78%, 68% and 41%, respectively. One, 3, and 5 year OS from
diagnosis and fromaHSCTwere81, 66, and66%and89, 66 and
66% respectively (Table 1). The 100-day and 1 year TRMwere
3.4% (1 patient) and 6.9% (2 patients), respectively.
Conclusion: Our results show that autologous HSCT is
a reasonable option for patients with newly diagnosed AL
amyloidosis. The 100 day and 1 year TRM compares favorably
to multiple myeloma patients undergoing autologous HSCT.146
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